Elevated cardiac biomarkers have also been associated with worse outcomes and or cardiac hemodynamic instability, including cytokine release syndrome from chimeric antigen therapy (CAR-T), heart failure from proteasome inhibitor use (i.e., carfilzomib), or myocarditis from immune checkpoint inhibitor therapy [38–41].